Adult Acute Minimally Differentiated Myeloid Leukemia (M0)

Explore clinical trials studying Adult Acute Minimally Differentiated Myeloid Leukemia (M0). Study availability and eligibility vary by location and protocol.

37 public trials 0 recruiting studies

Refine in advanced search Browse all conditions

Adult Acute Minimally Differentiated Myeloid Leukemia (M0) trial results

Completed

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00027872

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, +35 more
Locations: Johns Hopkins University Baltimore, Maryland, United States

View Trial Details

Completed

XK469R in Treating Patients With Refractory Hematologic Cancer

NCT00095797

Conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), +66 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00101296

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), +31 more
Locations: City of Hope Duarte, California, United States

View Trial Details

Completed

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

NCT00093418

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), +29 more
Locations: Southwest Oncology Group San Antonio, Texas, United States

View Trial Details

Completed

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

NCT00098826

Conditions: Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), +60 more
Locations: Case Western Reserve University Cleveland, Ohio, United States

View Trial Details

Completed

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

NCT00131989

Conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), +37 more
Locations: Johns Hopkins University Baltimore, Maryland, United States

View Trial Details

Completed

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT00112853

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), +27 more
Locations: Johns Hopkins University Baltimore, Maryland, United States

View Trial Details

Adult Acute Minimally Differentiated Myeloid Leukemia (M0)

Adult Acute Minimally Differentiated Myeloid Leukemia (M0) trial results

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

XK469R in Treating Patients With Refractory Hematologic Cancer

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Related conditions